companies with glp 1 drugs The U.S. Food and Drug Administration approved Eli Lilly's GLP-1 pill, the company said, a major milestone for the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications Shortages improve for Lilly's GLP-1
Description
2018;67[Suppl 1]:522-P

Examples of incretin mimetics include liraglutide, exenatide, semaglutide, and dulaglutide
Elkind-Hirsch KE, Chappell N, Seidemann E, et al
Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide

Tolerability and Safety Common side effects of popular GLP-1 medications are usually transient and can include: Nausea Diarrhea Constipation Early satiety Gastrointestinal upset during dose escalation Hydration, changes to meal size, and slower titration may help with these effects

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
